American Heart Journal
Volume 148, Issue 3 , Pages 371-377 , September 2004

Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: How can clinicians reduce the risks?

  • Debabrata Mukherjee, MD

      Affiliations

    • Division of Cardiology, University of Michigan, Ann Arbor, Mich, USA
    • ,
  • Mehmet Oz, MD

      Affiliations

    • Division of Cardiac Surgery, Columbia University, New York, NY, USA
    • ,
  • Richard Prager, MD

      Affiliations

    • Division of Cardiac Surgery, University of Michigan, Ann Arbor, Mich, USA
    • ,
  • Kim A. Eagle, MD

      Affiliations

    • Division of Cardiology, University of Michigan, Ann Arbor, Mich, USA
    • Corresponding Author InformationReprint requests: Kim A Eagle, MD, Division of Cardiology, University of Michigan Cardiovascular Center, 300 N Ingalls, NIB 8B02, Ann Arbor, MI 48109-0477, USA.

Received 28 February 2004 ,Accepted 14 April 2004.

References 

  1. Chaitman BR, Alderman EL, Sheffield LT, et al.  Use of survival analysis to determine the clinical significance of new Q waves after coronary bypass surgery. Circulation. 1983;67:302–309
  2. Schaff HV, Gersh BJ, Fisher LD, et al.  Detrimental effect of perioperative myocardial infarction on late survival after coronary artery bypass (report from the Coronary Artery Surgery Study—CASS). J Thorac Cardiovasc Surg. 1984;88:972–981
  3. Brener SJ, Lytle BW, Schneider JP, et al.  Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol. 2002;40:1961–1967
  4. Costa MA, Carere RG, Lichtenstein SV, et al.  Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation. 2001;104:2689–2693
  5. Steuer J, Horte LG, Lindahl B, et al.  Impact of perioperative myocardial injury on early and long-term outcome after coronary artery bypass grafting. Eur Heart J. 2002;23:1219–1227
  6. Klatte K, Chaitman BR, Theroux P, et al.  Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release (results from the GUARDIAN trial). J Am Coll Cardiol. 2001;38:1070–1077
  7. Januzzi JL, Lewandrowski K, MacGillivray TE, et al.  A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol. 2002;39:1518–1523
  8. Rasmussen C, Thiis JJ, Clemmensen P, et al.  Significance and management of early graft failure after coronary artery bypass grafting (feasibility and results of acute angiography and re-re-vascularization). Eur J Cardiothorac Surg. 1997;12:847–852
  9. Fuchs S, Kornowski R, Mehran R, et al.  Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077–1082
  10. Kugelmass AD, Cohen DJ, Moscucci M, et al.  Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 1994;74:748–754
  11. Abdelmeguid AE, Topol EJ, Whitlow PL, et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528–1536
  12. Califf RM, Abdelmeguid AE, Kuntz RE, et al.  Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–251
  13. Mehran R, Dangas G, Mintz GS, et al.  Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions (intravascular ultrasound study of 2256 patients). Circulation. 2000;101:604–610
  14. Ellis SG, Chew D, Chan A, et al.  Death following creatine kinase-MB elevation after coronary intervention (identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy). Circulation. 2002;106:1205–1210
  15. Ioannidis J, Karvouni E, Katritsis D. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406–1411
  16. Kini AS, Lee P, Marmur JD, et al.  Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93:18–23
  17. Nallamothu BK, Chetcuti S, Mukherjee D, et al.  Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol. 2003;91:1272–1274
  18. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al.  Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003;145:522–528
  19. Kizer JR, Muttrej MR, Matthai WH, et al.  Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J. 2003;24:1314–1322
  20. Liu PY, Li YH, Tsai WC, et al.  Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J. 2003;24:1824–1832
  21. Ricciardi MJ, Wu E, Davidson CJ, et al.  Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 2001;103:2780–2783
  22. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309–1317
  23. Bhatt DL, Chew DP, Hirsch AT, et al.  Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103:363–368
  24. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997;336:153–62
  25. Ferguson TB, Coombs LP, Peterson ED. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 2002;287:2221–2227
  26. Oosterga M, Voors AA, Pinto YM, et al.  Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol. 2001;87:542–546
  27. Kjoller-Hansen L, Steffensen R, Grande P. Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular function and no clinical heart failure. J Am Coll Cardiol. 2001;37:1214–1220
  28. Yusuf S, Sleight P, Pogue J, et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  29. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease (randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)). Lancet. 2003;362:782–788
  30. Gibbons RJ, Abrams J, Chatterjee K, et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article (a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina)). Circulation. 2003;107:149–158
  31. Topol EJ, Lincoff AM, Kereiakes DJ, et al.  Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1–6
  32. Kong DF, Hasselblad V, Harrington RA, et al.  Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003;92:651–655
  33. Lincoff AM, Bittl JA, Harrington RA, et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention (REPLACE-2 randomized trial). JAMA. 2003;289:853–863
  34. Chan AW, Bhatt DL, Chew DP, et al.  Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691–696
  35. Chan AW, Quinn MJ, Bhatt DL, et al.  Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:669–675
  36. Steinhubl SR, Berger PB, Mann JT, et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention (a randomized controlled trial). JAMA. 2002;288:2411–2420
  37. Mehta SR, Yusuf S, Peters RJ, et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention (the PCI-CURE study). Lancet. 2001;358:527–533
  38. Gum PA, Kottke-Marchant K, et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  39. Gaudino M, Nasso G, Zamparelli R, et al.  Inflammatory and fibrinolytic activation after coronary artery bypass with extracorporeal circulation [in Italian]. Ital Heart J. 2002;3:646–651
  40. Almagor M, Keren A, Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J. 2003;145:248–253
  41. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570–580
  42. Willerson J, Cohen L, Maser A. Pathophysiology and clinical recognition. In:  Willerson J,  Cohn J editor. Cardiovascular medicine. New York: Churchill Livingston; 1995;p. 333–365
  43. Lefkovits J, Holmes DR, Califf RM, et al.  Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. Circulation. 1995;92:734–740
  44. Sharma SK, Kini A, Marmur JD, et al.  Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention (benefit is extended to improvement in intermediate-term survival). Circulation. 2000;102:166–172
  45. DeFoe GR, Ross CS, Olmstead EM, et al.  Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 2001;71:769–776
  46. Toyofyuku M, Imazu M, Sumii K, et al.  Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis. 2002;160:339–344
  47. Chang PP, Sussman MS, Conte JV, et al.  Postoperative ventricular function and cardiac enzymes after on-pump versus off-pump CABG surgery. Am J Cardiol. 2002;89:1107–1110
  48. Kim KB, Kang CH, Chang WI, et al.  Off-pump coronary artery bypass with complete avoidance of aortic manipulation. Ann Thorac Surg. 2002;74:S1377–1382
  49. Ascione R, Lloyd CT, Gomes WJ, et al.  Beating versus arrested heart revascularization (evaluation of myocardial function in a prospective randomized study). Eur J Cardiothorac Surg. 1999;15:685–690
  50. Krejca M, Skiba J, Szmagala P, et al.  Cardiac troponin T release during coronary surgery using intermittent cross-clamp with fibrillation, on-pump and off-pump beating heart. Eur J Cardiothorac Surg. 1999;16:337–341
  51. Puskas JD, Williams WH, Duke PG, et al.  Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay (a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting). J Thorac Cardiovasc Surg. 2003;125:797–808
  52. Dewey TM, Magee MJ, Acuff T, et al.  Beating heart surgery reduces mortality in the reoperative bypass patient. Heart Surg Forum. 2002;5(Suppl 4):S301–316
  53. Nathoe HM, van Dijk D, Jansen EW, et al.  A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med. 2003;348:394–402
  54. Fillinger MP, Surgenor SD, Hartman GS, et al.  The association between heart rate and in-hospital mortality after coronary artery bypass graft surgery. Anesth Analg. 2002;95:1483–1488
  55. Cannon CP, Braunwald E, McCabe CH, et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  56. Nissen SE, Tuzcu EM, Schoenhagen P, et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis (a randomized controlled trial). JAMA. 2004;291:1071–1080

☆ Am Heart J 2004;148:371–7.

PII: S0002-8703(04)00209-1

doi: 10.1016/j.ahj.2004.04.012

American Heart Journal
Volume 148, Issue 3 , Pages 371-377 , September 2004

Article Tools